In addition, in any case in which a prescription is issued to a new patient, either on or after the effective date of P.L. 2017, c. 341(C.45:16-9.4c et al.), for a Schedule II controlled dangerous substance or opioid drug that has been prescribed for acute or chronic pain, or for a benzodiazepine drug that is a Schedule III or IV controlled dangerous substance, the practitioner or other authorized person shall access prescription monitoring information on a quarterly basis during the period of time the patient continues to receive such prescription.
N.J.S. § 45:1-46.1